{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:56:44Z","timestamp":1794895004638,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01779-x","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:53:36Z","timestamp":1779004416000},"page":"3415-3429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial"],"prefix":"10.1007","volume":"16","author":[{"given":"Nina","family":"Magnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiram","family":"Ruiz-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bukhalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja K.","family":"Sivamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Stakias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Espaillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"4","key":"1779_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1779_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS ONE. 2012;7(12):e52935.","journal-title":"PLoS ONE"},{"issue":"1","key":"1779_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjd.16332","volume":"179","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173\u201381.","journal-title":"Br J Dermatol"},{"issue":"19","key":"1779_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"2","key":"1779_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12788\/cutis.0701","volume":"111","author":"NP Del Toro","year":"2023","unstructured":"Del Toro NP, Wu JJ, Han G. New treatments for psoriasis: an update on a therapeutic frontier. Cutis. 2023;111(2):101\u20134.","journal-title":"Cutis"},{"issue":"9","key":"1779_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s13555-022-00775-1","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Xia Q, John AR, Patel V, Seigel L. Treatment patterns for targeted therapies, non-targeted therapies, and drug holidays in patients with psoriasis. Dermatol Ther. 2022;12(9):2087\u2013103.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1779_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1779_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/24755303241302070","volume":"10","author":"B Strober","year":"2024","unstructured":"Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, et al. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the international psoriasis council guidelines in patients in North America. J Psoriasis Psoriatic Arthritis. 2024;10(1):22\u20137.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"3","key":"1779_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1779_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jdv.15174","volume":"33","author":"MT Wan","year":"2019","unstructured":"Wan MT, Alvarez J, Shin DB, Dommasch ED, Wu JJ, Gelfand JM. Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol. 2019;33(1):42\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1779_CR11","volume":"8","author":"E Sbidian","year":"2025","unstructured":"Sbidian E, Chaimani A, Guelimi R, Tai CC, Beytout Q, Choudhary C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2025;8(8):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1779_CR12","first-page":"258","volume":"92","author":"SR Feldman","year":"2013","unstructured":"Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92(5):258\u201363.","journal-title":"Cutis"},{"issue":"1","key":"1779_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1779_CR14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"K Ronholt","year":"2017","unstructured":"Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"1779_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","volume":"65","author":"ED Schadler","year":"2019","unstructured":"Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Dis Mon. 2019;65(3):51\u201390.","journal-title":"Dis Mon"},{"issue":"1","key":"1779_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol."},{"issue":"10198","key":"1779_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"10148","key":"1779_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"5","key":"1779_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LF Stein Gold","year":"2023","unstructured":"Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540\u201352.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1779_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","volume":"310","author":"AG Florek","year":"2018","unstructured":"Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271\u2013319.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1779_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40273-013-0126-6","volume":"32","author":"A Torbica","year":"2014","unstructured":"Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1779_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1779_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1779_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1779_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/jdv.12555","volume":"29","author":"KA Papp","year":"2015","unstructured":"Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, et al. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol. 2015;29(2):361\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1779_CR26","unstructured":"Kalola UK, Alberty A, Sheehy C. Deucravacitinib. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Anastasia Alberty declares no relevant financial relationships with ineligible companies. Disclosure: Conor Sheehy declares no relevant financial relationships with ineligible companies.2026."},{"issue":"9","key":"1779_CR27","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"1779_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9(1):5\u201318.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1779_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1779_CR30","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1111\/jdv.16568","volume":"34","author":"J Seneschal","year":"2020","unstructured":"Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1779_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180\u20135.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1779_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1779_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.e1-30.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1779_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, Stein Gold L, Flower A, Jardon S, et al. Patient and physician perceptions of psoriatic disease in the united states: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023;13(6):1329\u201346.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1779_CR35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archdermatol.2011.309","volume":"147","author":"ML Schaarschmidt","year":"2011","unstructured":"Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285\u201394.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1779_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s13555-023-01089-6","volume":"14","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, et al. Evaluating treatment choice in patients with moderate to severe psoriasis in the united states: results from a US Patient survey. Dermatol Ther (Heidelb). 2024;14(2):421\u201339.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1779_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1779_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","volume":"7","author":"M Alcusky","year":"2017","unstructured":"Alcusky M, Lee S, Lau G, Chiu GR, Hadker N, Deshpande A, et al. Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. Dermatol Ther. 2017;7(4):463\u201383.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1779_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2340\/00015555-2834","volume":"98","author":"ML Schaarschmidt","year":"2018","unstructured":"Schaarschmidt ML, Herr R, Gutknecht M, Wroblewska K, Gerdes S, Sticherling M, et al. Patients\u2019 and physicians\u2019 preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200\u20135.","journal-title":"Acta Derm Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01779-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:23:57Z","timestamp":1781753037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01779-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01779-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nina Magnolo has served as advisor and\/or paid speaker for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Dr. Wolff, Eli Lilly, Janssen, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Jennifer Soung has served as a research investigator, scientific adviser, and\/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Castle Biosciences, Celgene, Dermavant, Eli Lilly, Incyte, Johnson & Johnson, KoBioLabs, Kyowa Kirin, LEO Pharma, National Psoriasis Foundation (nonprofit), Novartis, Ortho Dermatologics, Pfizer, Regeneron\/Sanofi, and UCB. John Frew has conducted advisory work for AbbVie, Actor Pharma, Agilex, Amgen, Apogee, Avalo Therapeutics, Azora, Boehringer-Ingelheim, Bristol-Myers Squibb, Chemocentryx, CSL Behring, Deepcure, Elasmogen, Elgia, Eli Lilly, Fortrea, Frazier, Galderma, Gilde Healthcare, InflaRx, Johnson and Johnson, Kyowa Kirin, LEO Pharma, Medici, Mirador Therapeutics, Moonlake, Nested Therapeutics, Novartis, Regeneron, RxMx, Sanofi, Sonoma Bio, Takeda, UCB, Wiley, Zura Bio; has conducted clinical trials for: AbbVie, Amgen, Avalo Therapeutics, Azora, Boeringer Ingelheim, Bristol Myer Squibb, Chemocentryx, CSL Behring, Eli Lilly, Galderma, InflaRx, Johnson and Johnson, LEO, Moonlake, Novartis, Regeneron, Sanofi, Takeda, UCB; and has received research support from Almirall, Apogee, Avalo Therapeutics, Elasmogen, La Roche Posay, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda Pharmaceuticals, UCB. Antonio Costanzo reported receiving grants from AbbVie during the conduct of the study; grants from Galderma and Novartis; and personal fees from Eli Lilly, Janssen, Sanofi, and UCB outside the submitted work. Hiram Ruiz-Santiago has participated in AbbVie-funded studies. He has received honoraria as a speaker and\/or advisory board member from AbbVie, Janssen, Elly Lilly, and Bristol Myers Squibb. Killian Eyerich has received honoraria as a speaker and\/or advisory board member from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Sanofi, and UCB. Mar Llamas-Velasco has been an advisory board member, consultant, research support, participated in clinical trials, and\/or received honoraria for speaking with the following pharmaceutical companies: AbbVie, Almirall, Amgen, Boehringer, Celgene, Janssen, Leo, Lilly, Kyowa Kirin, Novartis, and UCB. Michael Bukhalo is an investigator on an AbbVie-funded study. Raja K. Sivamani serves as an investigator for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Codex Labs, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Merck, Moonlake, Novartis, and UCB. He serves as a consultant or speaker for AbbVie, Arbonne, Arcutis, Burt\u2019s Bees, Bristol Myers Squibb, Codex Labs, Eli Lilly, Galderma, Incyte, Leo, Novartis, Nutrafol, Pfizer, Phothera, Regeneron Pharmaceuticals, Sanofi, Sun, Trace Minerals, and UCB. Angela Moore has received honoraria or research funds from AbbVie, Aclaris, Acrotech, Arcutis, Bayer, Bristol Myers Squibb, Cara, Eli Lilly, Galderma, Genentech Roche, Incyte, Janssen, Novartis, Pfizer, Rapt, Regeneron, Roche, and Sanofi.Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, and Ramon Espaillat are employees of AbbVie and may hold stock options. Richard B. Warren has received grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, and UCB. He has received personal fees from AbbVie, AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Immunocore, Janssen, Lilly, Leo, Meiji Pharma, Nektar Therapeutics, Novartis, Pfizer, RAPT Pharmaceuticals, Sanofi, Sun Pharma, Takeda, UCB & UNION. Richard B. Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      . Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}